ESMO Advanced Course on Early Drug Development 2023: Singapore

Learning objectives

• To foster, educate and mentor the next generation of Phase I/Early Drug Development Programmes in Oncology centres from both the established and emerging economies in the Asia-Pacific region.
• To understand the fundamentals of establishing and running a successful Phase I/Early Drug Development Programme: from an in-depth understanding of trial selection to patient coordination, to running a programme, to effectively engaging with sponsors and fellow PIs, to regional and international engagement, and regulatory processes. 
• To bridge the gap between the key stakeholders in the drug development process in the Asia-Pacific region: investigators, sponsors (Pharma and Biotech), Contract Research Organization (CRO), regulatory bodies.

Download the programme

Accreditation

The programme of this event have been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

• Jayesh Desai, Australia
• Elena Garralda, Spain
• Brigette Ma, Hong Kong SAR, China